To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.

An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.

To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.

Inclusion Criteria:

• Must have met the inclusion criteria for the preceding double-blind BID study in painful diabetic peripheral neuropathy
• Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.

Exclusion Criteria:

• Patients may not participate if they experienced a serious adverse event during the preceding double-blind BID study which was determined to be related to the study medication.